Last reviewed · How we verify

CHLORTETRACYCLINE HYDROCHLORIDE

FDA-approved approved Small molecule

Chlortetracycline hydrochloride inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the ribosome.

Chlortetracycline hydrochloride is an older broad-spectrum antibiotic that belongs to the tetracycline class. It is primarily used for treating bacterial infections, but due to its age and the availability of newer antibiotics, it is less commonly prescribed today. The drug works by inhibiting bacterial protein synthesis, making it effective against a wide range of Gram-positive and some Gram-negative bacteria. Despite its efficacy, chlortetracycline has several limitations, including potential side effects and the risk of bacterial resistance. Its use is generally reserved for specific cases where other antibiotics may not be suitable.

At a glance

Generic nameCHLORTETRACYCLINE HYDROCHLORIDE
Drug classTetracycline
Target30S ribosomal subunit
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved
First approval1950

Mechanism of action

The drug interferes with the bacterial ribosome's ability to synthesize proteins, which are essential for bacterial growth and survival.

Approved indications

Common side effects

Drug interactions

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: